Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia.

Narasimhan, Mythreyi; Khamkar, Vaishnavi; Tilwani, Sarika; Dalal, Sorab N; Shetty, Dhanlaxmi; Subramanian, P G; Gupta, Sanjay; Govekar, Rukmini

Narasimhan, Mythreyi; Khamkar, Vaishnavi; Tilwani, Sarika; Dalal, Sorab N; Shetty, Dhanlaxmi; Subramanian, P G; Gupta, Sanjay; Govekar, Rukmini.

Afiliación

Narasimhan M; Rukmini Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Khamkar V; Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India.
Tilwani S; Rukmini Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Dalal SN; Sorab Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Shetty D; Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India.
Subramanian PG; Sorab Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Gupta S; Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India.
Govekar R; Department of Cancer Cytogenetics, , ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.

J Cell Commun Signal ; 16(2): 207-222, 2022 Jun.

Article en En | MEDLINE | ID: mdl-34596797

Palabras clave

Bcr-Abl1; Chronic myeloid leukemia; Imatinib resistance; Mass spectrometry; Proteomics; p38-MAPK

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: J Cell Commun Signal Año: 2022 Tipo del documento: Article País de afiliación: India